ClinicalTrials.gg
CompletedNCT03282851Updated Feb 12, 2020

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

A Phase 1 interventional study of MSB11456 and US-licensed Actemra in Healthy, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 2 sites in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
696
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study aims to compare the PK/PD of a single injection of investigational Medicinal Product (IMP) MSB11456, US licensed Actemra and EU approved RoActemra in healthy adult subjects.

02

Conditions studied

  • Healthy

Keywords

  • MSB11456
  • Actemra®
  • RoActemra®
03

In context

Lead sponsor

Fresenius Kabi SwissBioSim GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects, 18 to 55 years of age, with a (BMI) between 18 and 29.9 kilogram per meter square (kg/m\^2).
  • Subjects who are on adequate as defined in the protocol and are willing and able to comply with the scheduled study visits, medicinal product (IMP) administration, safety laboratory tests, and all other study procedures.
  • Other protocol defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • Subjects with history and/or current presence of atopic allergy (for example, asthma including childhood asthma, urticaria, angio-edema, eczematous dermatitis).
  • Subjects with or allergic reactions, including known or suspected clinically relevant drug hypersensitivity to any components of the IMP formulations, comparable drugs, or to latex.
  • Subjects who have active or latent tuberculosis as indicated by a positive QuantiFERON®-Tuberculosis (TB) Gold test or a history of tuberculosis, lifetime history of invasive systemic fungal infections (for example, histoplasmosis) or other opportunistic infections, including recurrent or chronic local fungal infections, frequent (more than 3 per year requiring treatment) chronic or recurrent infections, having previously been treated with tocilizumab or taken a recombinant monoclonal antibody.
  • Subjects who have received a within 12 weeks before enrolling in this study or planning for any such vaccination during the study or within 4 months after IMP administration.
  • Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
696 participants (actual)

Study arms

  • Experimental
    MSB11456

    Drug: MSB11456

  • Active comparator
    US-licensed Actemra

    Drug: US-licensed Actemra

  • Active comparator
    EU-approved RoActemra

    Drug: EU-approved RoActemra

Interventions

  • Subjects will receive a single injection of MSB11456 on Day 1.

  • DrugUS-licensed Actemra

    Subjects will receive a single injection of US-licensed actemra on Day 1.

  • DrugEU-approved RoActemra

    Subjects will receive a single injection of EU-approved RoActemra on Day 1.

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  2. Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  3. Maximum Observed Serum Concentration (Cmax) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

Secondary outcomes

  1. Area Under Curve From Tme Zero to 72 Hours After Dosing (AUC 0-72) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  2. Percentage of Area Under Curve From Zero to Infinity (AUC0-∞) Obtained by Extrapolation (AUC extra%) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  3. Time To Reach Maximum Serum Concentration (tmax) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  4. Time to Last Observed Serum Concentration (tlast) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  5. Apparent Terminal Rate Constant (λz) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  6. Apparent Terminal Half-life (t½) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  7. Apparent Total Body Clearance of Drug from Serum Following Subcutaneous Administration (CL/F) of MSB11456, US-licensed Actemra, and EU-approved RoActemra

    Time frame: Up to Day 48

  8. Safety Profile as Assessed by Incidence of Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Injection Site Reactions, Laboratory Variables, Vital Signs and Electrocardiogram (ECG) Measurements

    Time frame: Up to Day 48

  9. Immunogenicity as Assessed by Incidence of Antidrug Antibodies (ADAs), Neutralizing Antibodies (NABs)

    Time frame: Up to Day 48

07

Study locations

2 sites
  • Research site
    Auckland, New Zealand
  • Research site
    Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Oct 2019, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2017
First posted
Sep 14, 2017
StartActual
Nov 27, 2017
Primary completionActual
Oct 1, 2019
CompletionActual
Oct 1, 2019
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03282851
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Nov 27, 2017
Primary completion
Oct 1, 2019
Completion
Oct 1, 2019
Last update
Feb 12, 2020

Study contacts

Medical Responsible
study director · Fresenius Kabi SwissBioSim GmbH

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion